Bayer taps LaCaze to head new oncology unit

Bayer has selected Robert LaCaze to serve as executive vice president in charge of the company’s new Oncology Strategic Business Unit at the Pharmaceuticals Division.
LaCaze will help manage and deliver upon Bayer’s growing oncology portfolio, which includes Nexavar, Xofigo and Stivarga. LaCaze comes to the role from within Bayer; as he currently serves as senior vice president and head of the Global Oncology Therapeutic Area within the Pharmaceuticals Division. As part of his new role, LaCaze will become a member of the Pharmaceuticals Division’s Executive Committee.
“We are delighted to have an executive with Robert LaCaze’s experience and talent lead the Oncology Strategic Business Unit,” Dieter Weinand, Bayer AG Board Member, said in a news release. “I am confident that he will contribute his expertise and foresight to help strengthen our efforts in the fight against cancer.”
The new business unit plans to combine Experimental Medicine Oncology, Clinical Pharmacology Oncology, early and late Project Management Oncology, Oncology Strategic Regulatory Affairs and Clinical Development Oncology. Additionally, the unit will include Oncology Strategic Marketing, Oncology Access and Pricing, Medical Affairs for Oncology globally, early oncology commercialization and certain operational functions.